Loading...

Abbisko Cayman Limited

2256.HK•HKSE
Healthcare
Biotechnology
HK$10.33
HK$-0.31(-2.91%)

Abbisko Cayman Limited (2256.HK) Stock Overview

Explore Abbisko Cayman Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 72.1/100

Key Financials

Market Cap6.9B
P/E Ratio207.25
EPS (TTM)$0.04
ROE0.01%
Fundamental Analysis

AI Price Forecasts

1 Week$10.01
1 Month$10.03
3 Months$11.03
1 Year Target$8.41

2256.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Abbisko Cayman Limited (2256.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.46, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $8.41.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 207.25 and a market capitalization of 6.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;